Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Gabapentin
|
| gptkbp:activities |
calcium channel modulator
|
| gptkbp:appointed_by |
oral capsule
oral solution |
| gptkbp:approves |
gptkb:2004
gptkb:FDA |
| gptkbp:brand |
gptkb:Lyrica_CR
gptkb:Lyrica_Capsules Lyrica Solution |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:combatants |
plasma proteins
|
| gptkbp:contraindication |
hypersensitivity to pregabalin
|
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:dosage_form |
gptkb:beer
gptkb:software_framework |
| gptkbp:duration |
varies by condition
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
extended-release
immediate-release |
| https://www.w3.org/2000/01/rdf-schema#label |
Pregabalin
|
| gptkbp:indication |
anxiety disorders
postherpetic neuralgia seizure disorders neuropathic pain associated with diabetic peripheral neuropathy |
| gptkbp:ingredients |
C8 H17 N O2
|
| gptkbp:interacts_with |
gptkb:beer
benzodiazepines opioids |
| gptkbp:is_atype_of |
N03 A X16
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_used_for |
fibromyalgia
generalized anxiety disorder neuropathic pain partial seizures |
| gptkbp:lifespan |
6.3 hours
|
| gptkbp:marketed_as |
gptkb:Lyrica
|
| gptkbp:metabolism |
kidneys
|
| gptkbp:safety_features |
C (during pregnancy)
|
| gptkbp:side_effect |
dizziness
drowsiness dry mouth weight gain blurred vision |
| gptkbp:symptoms |
anxiety
nausea insomnia sweating |
| gptkbp:treatment |
effective for anxiety
effective for chronic pain |
| gptkbp:type_of |
148553-50-8
|